Hemostasis activation in thrombophilic subjects with or without a history of venous thrombosis

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 1, 2008, Pages 55-62

  Cuderman, Tjaša Vižintin ^a   Božič, Mojca ^a   Peternel, Polona ^a   Stegnar, Mojca ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Hemostasis activation; Markers; Thrombophilia; Venous thrombosis

Indexed keywords

FIBRIN DEGRADATION PRODUCT; LUPUS ANTICOAGULANT; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTHROMBIN TIME; STATISTICAL SIGNIFICANCE; STRATIFICATION; THROMBOPHILIA; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PROTEIN C DEFICIENCY; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 37548998655     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607304408     Document Type: Article

References (27)

1. Bertina RM Molecular risk factors for thrombosis. Thromb Haemost. 1999 ; 82: 601-609.
2. Rosendaal FR Venous thrombosis: a multicausal disease. Lancet. 1999 ; 353: 1167-1173.
3. Mannucci PM Markers of hypercoagulability in cancer patients. Haemostasis. 1997 ; 27 (suppl 1). 25-31.
4. Bauer KA, Rosenberg RD The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood. 1987 ; 70: 343-350.
5. Demers C., Ginsberg JS, Henderson P., Ofosu FA, Weitz JI, Blajchman MA Measurement of markers of activated coagulation in antithrombin III deficient subjects. Thromb Haemost 1992 ; 67: 542-544.
6. Mannucci PM, Tripodi A., Bottasso B., et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost. 1992 ; 67: 200-202.
7. Bauer KA, Broekmans AW, Bertina RM, et al. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood. 1988 ; 71: 1418-1426.
8. Zoller B., Holm J., Svensson P., Dahlback B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC resistance) and/or inherited protein S deficiency. Thromb Haemost. 1996 ; 75: 270-274.
9. Martinelli I., Bottasso B., Duca F., Faioni E., Mannucci PM Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost. 1996 ; 75: 703-705.
10. Simioni P., Scarano L., Gavasso S., et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol. 1996 ; 92: 435-441.
11. Mercuri F., Giacomello R., Puglisi F., et al. Factor V Leiden increases plasma F1+2 levels in both normal and deep venous thrombosis subjects. Haematologica. 2000 ; 85: 386-389.
12. Kyrle PA, Eichinger S., Pabinger I., et al. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism. Thromb Haemost. 1997 ; 77: 829-833.
13. Bauer KA, Humphries S., Smillie B., et al. Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thromb Haemost. 2000 ; 84: 396-400.
14. Ames PR, Tommasino C., Iannaccone L., Brillante M., Cimino R., Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - a crucial role for acquired protein S deficiency. Thromb Haemost. 1996 ; 76: 190-194.
15. Kyrle PA, Stuempflen A., Hirschl M., et al. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. Thromb Haemost. 1997 ; 78: 1327-1331.
16. O'Donnell J., Mumford AD, Manning RA, Laffan MA Marked elevations of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol. 2001 ; 115: 687-691.
17. Kyrle PA, Mannhalter C., Beguin S., et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol. 1998 ; 18: 1287-1291.
18. Eichinger S., Weltermann A., Philipp K., et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost. 1999 ; 82: 1232-1236.
19. Lowe GD, Rumley A., Woodward M., Reid E., Rumley J. Activated protein C resistance and the FV:R506Q mutation in a random population sample. Thromb Haemost. 1999 ; 81: 918-924.
20. Macherel P., Sulzer I., Furlan M., Lammle B. Determination of thrombin-antithrombin-III-complex is not a suitable screening test for detecting deficiency of protein C or protein S. Thromb Res. 1992 ; 66: 775-777.
21. Božǐc M., Teran N., Kunej T., et al. Does the improvement of the method for resistance to activated protein C decrease the need for DNA analysis? Farm Vestn. 2000 ; 51: 427.
22. Tukey JW Exploratory Data Analysis. Reading, MA: Addison-Wesley ; 1977: 506.
23. Palareti G., Legnani C., Cosmi B., et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003 ; 108: 313-318.
24. Arkel YS, Paidas MJ, Ku DH The use of coagulation activation markers (soluble fibrin polymer, TpP™, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagul Fibrinolysis. 2002 ; 13: 199-205.
25. Palareti G., Legnani C., Cosmi B., Guazzaloca G., Pancani C., Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002 ; 87: 7-12.
26. Greenberg CS, Hursting MJ, Macik BG, et al. Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. Clin Chem. 1994 ; 40: 1962-1969.
27. Stegnar M., Vižintin Cuderman T., Božic M. Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability. Clin Chem Lab Med. 2007 ; 45: 40-6.